Prospects of Chemotherapy for Gastrointestential Stromal Colon Tumours
https://doi.org/10.24060/2076-3093-2020-10-3-249-253
Abstract
Gastrointetinal stromal tumours are the most common primary mesenchymal tumours of the gastrointestinal tract. According to statistical data, the annual incidence of this pathology in Russia comprises 13 patients per 1 million inhabitants, i.e. about 2,000 patients per year on average. In the United States, 3,000–4,000 cases are registered every year. This article discusses general and specific issues associated with morbidity and mortality from gastrointestinal stromal tumours, as well as reasons for the low efficacy of surgical and targeted therapies. Methods for combined treatment of patients with gastrointestinal stromal tumours are proposed. The treatment of such pathologies has evolved with the development of immunohystochemical analytical procedures and therapies against KIT/PDGFRA-specific protooncogenes, as well as the emergence of low-molecular kinase inhibitors. However, the probability of non-recurrence survival can only be increased by complete surgical removal of gastrointestinal stromal colon tumours. In the surgical treatment, three main approaches are defined: the initial stage of treatment, provided that the tumour is resectable and has a small size; surgical treatment after neoadjuvant therapy; symptomatic treatment, so-called ‘debulking surgery’. Adjuvant targeted therapy with Imatinib provides for a high objective response. The use of Imatinib chemotherapy determines the efficacy and radicality of surgical treatment in most cases. In general, the question of treating gastrointestinal stromal colon tumours is still relevant, requiring further research and objective evaluation of all technical and tactical approaches in the context of distant results.
About the Authors
A. R. Mukhamediyarov
Kuvatov Republican Clinical Hospital
Russian Federation
Russian Federation
Oncology Department,
Ufa
L. I. Bashirova
Bashkir State Medical University
Russian Federation
Russian Federation
Department of Pharmacology with a course of Clinical Pharmacology,
Ufa
A. I. Maksyutova
Burnazyan Federal Medical Biophysical Centre
Russian Federation
Russian Federation
Resident,
Moscow
A. T. Gattarova
Burnazyan Federal Medical Biophysical Centre
Russian Federation
Russian Federation
Resident,
Moscow
References
1. Nikulin M.P., Stilidi I.S. Epidemiology of gastrointestinal stromal tumors. Register in Russia: first experience. Journal of Modern Oncology. 2009;11(2):50–3 (In Russ.).
2. Joensuu H., Eriksson M., Sundby Hall K., Hartmann J.T., Pink D., Schütte J., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72. DOI: 10.1001/jama.2012.347
3. Schöffel N., Groneberg D.A., Kaul T., Laatsch D., Thielemann H. Gastrointestinal stromal tumors (GIST) — literature review. MMW Fortschr Med. 2016;158(3):60–2. DOI: 10.1007/s15006-016-7824-x
4. López-Tomassetti Fernández E.M., Hernández Hernández J.R., Nuñez Jorge V. Perforated gastrointestinal stromal tumor in Meckel’s diverticulum treated laparoscopically. Asian J Endosc Surg. 2013;6(2):126–9. DOI: 10.1111/ases.12016
5. Prablek M., Srinivasan V.M., Srivatsan A., Holdener S., Oneissi M., Heck K.A., et al. Gastrointestinal stromal tumor with intracranial metastasis: case presentation and systematic review of literature. BMC Cancer. 2019;19(1):1119. DOI: 10.1186/s12885-019-6316-7
6. Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019;35(6):555–9. DOI: 10.1097/MOG.0000000000000584
7. Demetri G.D., Titton R.L., Ryan D.P., Fletcher C.D. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J Med. 2004;351(17):1779–87. DOI: 10.1056/NEJMcpc049024
8. Liu L., Zhu Y., Wang D., Yang C., Zhang Q.I., Li X., et al. Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report. Oncol Lett. 2016;11(5):3303–7. DOI: 10.3892/ol.2016.4420
9. Waidhauser J., Bornemann A., Trepel M., Märkl B. Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia. World J Gastroenterol. 2019;25(30):4261–77. DOI: 10.3748/wjg.v25.i30.4261
10. Kawanowa K., Sakuma Y., Sakurai S., Hishima T., Iwasaki Y., Saito K., et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol. 2006;37(12):1527–35. DOI: 10.1016/j.humpath.2006.07.002
11. Tan C.B., Zhi W., Shahzad G., Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol. 2012;2012:595968. DOI: 10.5402/2012/595968
12. Ip C.K.M., Ng P.K.S., Jeong K.J., Shao S.H., Ju Z., Leonard P.G., et al. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun. 2018;9(1):4583. DOI: 10.1038/s41467-018-06949-w
13. Safonov A.S., Zabelin M.V. Making colostomy from short-scar incision and colorectal stenting in acute colonic obstruction of tumoral genesis. Healthcare, education and security. 2017;(3):42–8 (In Russ.).
14. Khoshnood A. Gastrointestinal stromal tumor — A review of clinical studies. J Oncol Pharm Pract. 2019;25(6):1473–85. DOI: 10.1177/1078155219846955
15. Nagaeva V.V., Kokoreva E.G., Eliseev E.V. Tissue-specific antibodies and duration of the disease: diagnostic and prognostic value. Healthcare, education and security. 2015;(2):17–9 (In Russ.).
16. Guo W., Yang Z., Wei Y., Qin X., Li C., Huang R., et al. Radical excision versus local resection for primary rectal gastrointestinal stromal tumors. Cohort Study. Int J Surg. 2020;77:190–7. DOI: 10.1016/j.ijsu.2020.03.068
17. Yang Z., Feng X., Zhang P., Chen T., Qiu H., Zhou Z., et al. Clinicopathological features and prognosis of 276 cases of primary small (≤2 cm) gastric gastrointestinal stromal tumors: a multicenter data review. Surg Endosc. 2019;33(9):2982–90. DOI: 10.1007/s00464-018-6564-7
18. Patel D.J., Lutfi W., Sweigert P., Eguia E., Abood G., Knab L., et al. Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): Is there a survival benefit following margin negative surgical resection? Am J Surg. 2020;219(3):436–9. DOI: 10.1016/j.amjsurg.2019.10.014
19. Wolfe C.R., Reyna V.F., Widmer C.L., Cedillos-Whynott E.M., BrustRenck P.G., Weil A.M., et al. Understanding genetic breast cancer risk: processing loci of the BRCA gist intelligent tutoring system. Learn Individ Differ. 2016;49:178–89. DOI: 10.1016/j.lindif.2016.06.009
20. Vetto J.T. Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs). Onco Targets Ther. 2009;2:151– 9. DOI: 10.2147/ott.s4740
21. Li G.Z., Raut C.P. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Onco Targets Ther. 2019;12:5123–33. DOI: 10.2147/OTT.S180763
22. Boichuk S., Galembikova A., Dunaev P., Valeeva E., Shagimardanova E., Gusev O., et al. Novel receptor tyrosine kinase switch promotes gastrointestinal stromal tumor drug resistance. Molecules. 2017;22(12):2152. DOI: 10.3390/molecules22122152
23. Laurent M., Brahmi M., Dufresne A., Meeus P., Karanian M., RayCoquard I., et al. Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives. Transl Gastroenterol Hepatol. 2019;4:24. DOI: 10.21037/tgh.2019.03.07
24. Kolesnik E.1, Lisnoy I.1, Mahmudov D.1, Lukashenko A.1, Priymak V.1, Zhukov Y. Results of a multimodal program Fast track surgery implementation in surgical treatment of patients with colon cancer. Eurasian journal of oncology. 2015;(2):85–97 (In Russ.).
25. Yamaoka T., Kusumoto S., Ando K., Ohba M., Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018;19(11):3491. DOI: 10.3390/ijms19113491
26. Taylor M., Coleman R.L., Sood A.K. The role of angiogenesis in cancer. In: Tsimberidou A.-M., Kurzrock R., Anderson K.C. (editors). Target therapy in translational cancer research. Wiley-Blackwell; 2015:64–71. DOI: 10.1002/9781118468678 27 Rajabi M., Mousa S.A. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34. DOI: 10.3390/biomedicines5020034
27. International Agency for Research on Cancer. World cancer report 2014. In: Stewart B.W., Wild C.P. (editors). World Cancer Report. Lyon: International Agency for Research on Cancer; 2015.
28. Zabelin M.V., Seryakov A.P., Safonov A.S. Colonic GIST: what do we know today? Coloproctology. 2015;(S1):67a–8 (In Russ.). 30 Joensuu H., Vehtari A., Riihimäki J., Nishida T., Steigen S.E., Brabec P., et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74. DOI: 10.1016/S1470-2045(11)70299-6
Review
For citations:
Mukhamediyarov A.R., Bashirova L.I., Maksyutova A.I., Gattarova A.T. Prospects of Chemotherapy for Gastrointestential Stromal Colon Tumours. Creative surgery and oncology. 2020;10(3):249-253. (In Russ.) https://doi.org/10.24060/2076-3093-2020-10-3-249-253
Views:
2077
Email this article 